Leadless pacing with Micra TPS: A comparison between right ventricular outflow tract, mid-septal, and apical implant sites.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
10 2019
Historique:
received: 22 04 2019
revised: 12 07 2019
accepted: 14 07 2019
pubmed: 25 7 2019
medline: 22 9 2020
entrez: 25 7 2019
Statut: ppublish

Résumé

With its steerable transcatheter delivery system, the Micra can be deployed in nonapical positions within the right ventricle, potentially allowing reduction of the paced QRS width. We sought to evaluate the safety and long-term performance of the right ventricular outflow tract (RVOT) pacing using the Micra transcatheter pacing system (TPS). We also compared the paced QRS between RVOT, mid-septal, and apical implant positions. All patients who underwent a Micra TPS implantation at the University Hospitals of Leuven were enrolled in this observational study. Right ventricular (RV) position of the device was assessed on per-procedural ventriculography. Paced QRS was analyzed and follow-up completed at 1 month and then every 6 months. Among the 133 patients included (mean follow-up: 13 ± 11 months), 45 were implanted in the RVOT, 58 midseptally, and 30 at the apex. All implant procedures were successful and no pericardial effusion was encountered within the 30 days post-implant. Two major complications were reported with devices implanted at the apex. Pacing impedance was significantly higher in the RVOT compared to the mid-septal and apical position (P < .001). Pacing threshold and R-wave amplitude did not differ over time in either position. The median narrowest paced QRS duration was observed in the RVOT (142 ms) compared to mid-septal (159 ms; P < .001), and apical position (181 ms; P < .001). Implantation of the Micra TPS in the RVOT is safe and feasible. Electrical performance over time was comparable to mid-septal and apical positions. The narrowest paced QRS complexes is achieved with RVOT pacing.

Sections du résumé

BACKGROUND
With its steerable transcatheter delivery system, the Micra can be deployed in nonapical positions within the right ventricle, potentially allowing reduction of the paced QRS width. We sought to evaluate the safety and long-term performance of the right ventricular outflow tract (RVOT) pacing using the Micra transcatheter pacing system (TPS). We also compared the paced QRS between RVOT, mid-septal, and apical implant positions.
METHODS
All patients who underwent a Micra TPS implantation at the University Hospitals of Leuven were enrolled in this observational study. Right ventricular (RV) position of the device was assessed on per-procedural ventriculography. Paced QRS was analyzed and follow-up completed at 1 month and then every 6 months.
RESULTS
Among the 133 patients included (mean follow-up: 13 ± 11 months), 45 were implanted in the RVOT, 58 midseptally, and 30 at the apex. All implant procedures were successful and no pericardial effusion was encountered within the 30 days post-implant. Two major complications were reported with devices implanted at the apex. Pacing impedance was significantly higher in the RVOT compared to the mid-septal and apical position (P < .001). Pacing threshold and R-wave amplitude did not differ over time in either position. The median narrowest paced QRS duration was observed in the RVOT (142 ms) compared to mid-septal (159 ms; P < .001), and apical position (181 ms; P < .001).
CONCLUSION
Implantation of the Micra TPS in the RVOT is safe and feasible. Electrical performance over time was comparable to mid-septal and apical positions. The narrowest paced QRS complexes is achieved with RVOT pacing.

Identifiants

pubmed: 31338871
doi: 10.1111/jce.14083
doi:

Types de publication

Comparative Study Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2002-2011

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Christophe Garweg (C)

Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Bert Vandenberk (B)

Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Stefaan Foulon (S)

Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Peter Haemers (P)

Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Joris Ector (J)

Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Rik Willems (R)

Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH